What is Neuron23?
Neuron23 Inc. is a biotechnology company dedicated to advancing precision medicines for genetically defined neurological and immunological diseases. By integrating cutting-edge human genetics with sophisticated artificial intelligence (AI)-enabled drug discovery and biomarker platforms, Neuron23 aims to accelerate the development of novel therapeutics. The company's strategic focus encompasses critical areas such as neurodegenerative diseases, neuroinflammatory conditions, and systemic autoimmune disorders, addressing significant unmet medical needs through a data-driven and scientifically rigorous approach.
How much funding has Neuron23 raised?
Neuron23 has raised a total of $310M across 4 funding rounds:
Series B
$80M
Series A
$33.5M
Series C
$100M
Series D
$96.5M
Series B (2020): $80M with participation from Cowen Healthcare Investments, Perceptive Advisors, HBM Partners, Kleiner Perkins, Surveyor Capital (a Citadel company), Redmile Group, Acorn Bioventures, and Westlake Village BioPartners
Series A (2020): $33.5M led by Kleiner Perkins and Westlake Village BioPartners
Series C (2022): $100M supported by Perceptive Advisors, Surveyor Capital, Acorn Bioventures, SoftBank Group, Redmile Group, Westlake Village BioPartners, Cowen Healthcare Investments, Kleiner Perkins, and HBM Partners
Series D (2025): $96.5M featuring Westlake Village BioPartners, HBM Healthcare Investments, Redmile Group, Softbank Vision Fund, Blue Owl, Acorn Bioventures, and Kleiner Perkins
Key Investors in Neuron23
Westlake Village BioPartners
Westlake Village BioPartners is a life science venture capital firm focused on investing in world-class entrepreneurs to create innovative biotech companies. Based in the Los Angeles biotech community, the firm incubates promising companies that aim to transform scientific breakthroughs into effective treatments for patients.
HBM Healthcare Investments
HBM Healthcare Investments is a publicly traded investment company focused on the global healthcare sector, with a diversified portfolio of private and publicly listed companies. The firm aims to capitalize on the significant growth opportunities within the healthcare market.
Redmile Group
Redmile Group LLC is a company that operates in the Venture Capital & Private Equity industry, headquartered in New York City, New York.
What's next for Neuron23?
With the recent infusion of $96.5M in a major strategic investment, Neuron23 is poised to accelerate its pipeline development and expand its research initiatives. This substantial backing, part of its overall $310M in capital, signals a transition towards later-stage development and potential commercialization. The company's advanced AI and genetic platforms are expected to drive further innovation in precision medicine, positioning Neuron23 to make significant strides in treating complex neurological and immunological diseases. Future growth will likely involve expanding clinical trials, forging strategic partnerships, and further refining its drug discovery engine to bring life-changing therapies to patients.
See full Neuron23 company page
